One missing metabolic step can turn cancer's DNA-copying machinery into a lethal weakness

Researchers at UT Southwestern Medical Center discovered that losing an enzyme called lipoylation disrupts cancer cell DNA replication, making them vulnerable to PARP inhibitor drugs.